Search

Your search keyword '"Srirajaskanthan, Rajaventhan"' showing total 327 results
Start Over Author "Srirajaskanthan, Rajaventhan"
327 results on '"Srirajaskanthan, Rajaventhan"'

103. S2023 Alpha Fetoprotein and Human Chorionic Gonadotrophin-β Are Prognostic Tumour Markers in Patients with Neuroendocrine Tumours

Author

Shah, Tahir, primary, Srirajaskanthan, Rajaventhan, additional, Bhogal, Maninder, additional, Toumpanakis, Christos, additional, Meyer, Tim, additional, Noonan, Aneesha, additional, Witney-Smith, Caroline, additional, Amin, Tejal, additional, Bhogal, Pervinder, additional, Sivathasan, Niroshan, additional, Warner, Ben D., additional, and Caplin, Martyn, additional

Published
2008
Full Text
View/download PDF

109. Parathyroid Hormone-Related Peptide-Secreting Pancreatic Neuroendocrine Tumours: Case Series and Literature Review.

Author

Srirajaskanthan, Rajaventhan, McStay, Mary, Toumpanakis, Christos, Meyer, Tim, and Caplin, Martyn E.

Subjects
*PARATHYROID hormone-related protein, *NEUROENDOCRINE tumors, *HYPERCALCEMIA, *LIVER transplantation, *DRUG therapy, *SOMATOSTATIN, *DIAGNOSIS, *THERAPEUTICS
Abstract

Background/Aims: Parathyroid hormone-related peptide (PTHrP) was discovered in 1987 as the tumour product responsible for humoral hypercalcaemia of malignancy (HHM). Pancreatic neuroendocrine tumours (NETs) are uncommon malignancies with an incidence of 1:100,000 population. PTHrP-secreting NETs are rare but are being recognised as a cause of HHM in NETs. We describe the largest series to date and the management of these rare tumours. Methods: One male and 4 female patients were seen in our unit from 1998 to 2006. The average duration of follow-up was 86 months from initial diagnosis. All patients had a histologically confirmed diagnosis of pancreatic NET, all of which were low-grade tumours. PTHrP assay was performed in 4 of 5 cases and was elevated in these patients. Results: Initial management involved surgery in 2 of 5 cases, whilst 2 cases underwent chemotherapy and 1 case was commenced on interferon-α. We discuss the further therapies that all patients underwent and the complexities that arose in managing disease progression as well as resistant hypercalcaemia. Conclusion: PTHrP-secreting tumours should be considered in the differential diagnosis of patients with NETs who present with hypercalcaemia and a disproportionately low PTH. PTHrP tumours may well be underestimated as the assay is difficult to perform and may not be requested. In hypercalcaemic patients the standard management acutely includes intravenous fluids, diuretics and intravenous bisphosphonate. In the further management, somatostatin analogue therapy is the first medical option to consider and we discuss the role of other therapies. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

111. Nutrition, diet therapy, and the liver

Author

Lakshman, Raj, Preedy, Victor R., Watson, Ronald Ross, Srirajaskanthan, Rajaventhan, Lakshman, Raj, Preedy, Victor R., Watson, Ronald Ross, and Srirajaskanthan, Rajaventhan

112. Nutrition, diet therapy, and the liver

Author

Lakshman, Raj, Preedy, Victor R., Watson, Ronald Ross, Srirajaskanthan, Rajaventhan, Lakshman, Raj, Preedy, Victor R., Watson, Ronald Ross, and Srirajaskanthan, Rajaventhan

113. Nutrition, diet therapy, and the liver

Author

Lakshman, Raj, Preedy, Victor R., Watson, Ronald Ross, Srirajaskanthan, Rajaventhan, Lakshman, Raj, Preedy, Victor R., Watson, Ronald Ross, and Srirajaskanthan, Rajaventhan

114. Nutrition, diet therapy, and the liver

Author

Lakshman, Raj, Preedy, Victor R., Watson, Ronald Ross, Srirajaskanthan, Rajaventhan, Lakshman, Raj, Preedy, Victor R., Watson, Ronald Ross, and Srirajaskanthan, Rajaventhan

115. Calcitonin secreting neuroendocrine neoplasms of the lung: a systematic review and narrative synthesis

Author

Llewellyn, David, Srirajaskanthan, Rajaventhan, Vincent, Royce, Guy, Catherine, Drakou, Eftychia E, Aylwin, Simon, Grossman, Ashley, Ramage, John K, and Dimitriadis, Georgios K

Abstract

Calcitonin-secreting neuroendocrine neoplasms of the lung are rare, with few cases reported in the literature. Differentiating between medullary thyroid carcinoma and an ectopic source of calcitonin secretion can represent a complex diagnostic conundrum for managing physicians, with cases of unnecessary thyroidectomy reported in the literature. This manuscript reports a case of ectopic hypercalcitonaemia from a metastatic neuroendocrine neoplasm of the lung with concurrent thyroid pathology and summarises the results of a systematic review of the literature. Medical Literature Analysis and Retrieval System Online, Excerpta Medica, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov and SCOPUS databases were systematically and critically appraised for all peer reviewed manuscripts that suitably fulfilled the inclusion criteria established a priori. The protocol for this systematic review was developed according to the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols, and followed methods outlined in The Cochrane Handbook for Systematic Reviews of Interventions. This systematic review is registered with PROSPERO. It is vital to consider diagnoses other than medullary thyroid carcinoma when presented with a patient with raised calcitonin, as it is not pathognomonic of medullary thyroid carcinoma. Lung neuroendocrine neoplasms can appear similar to medullary thyroid carcinoma histologically, they can secrete calcitonin and metastasize to the thyroid. Patients with medullary thyroid carcinoma may show stimulated calcitonin values over two or more times above the basal values, whereas calcitonin-secreting neuroendocrine neoplasms may or may not show response to stimulation tests. The present review summarises existing evidence from cases of ectopic hypercalcitonaemia to lung neuroendocrine neoplasms.

Published
2019
Full Text
View/download PDF

116. Personalised medicine strategies for patients with neuroendocrine tumours

Author

Basuroy, Ratnava Rono and Srirajaskanthan, Rajaventhan

Subjects
616.99
Abstract

dissection are used to resect localised rectal NENs. The treatment of advanced disease is multimodal. Data from the English bowel cancer-screening programme (BCSP), a double screening programme of faecal occult blood testing (FOBT) and colonoscopy, were analysed for NEN diagnoses. The incidence rates per 100,000 colonoscopies of NENs by anatomical site was 29 for rectal, 18 for colonic and 11 for ileal. The majority of rectal NENs had grade 1 (80%) and stage T1 (85%) disease. Over half of ileal NENs (54%) in this study had T3/4 invasive disease, with 85% having nodal and 36% having metastastatic disease. Putative carcinoid heart disease (CHD) markers were studied in comparison to the recommended NT-proBNP in cohorts of patients with CHD, functional and non- iii functional sbNENs. Calprotectin was elevated across all three groups while the remaining markers ST2, GAL3 and adrenomedullin were not elevated. NT-proBNP was significantly different in the CHD cohort when compared to the functional and non-functional groups. This supports the consensus guidance for NT-proBNP in assessing advanced CHD. Quantitative proteomic studies of fresh frozen G1 pancreatic NEN (pNEN) tissue were performed. 187 significant proteins mapped to cancer pathways, in particular RAS and PI3K-Akt signalling pathways. Ten proteins of interest were identified that may be involved in cancer development; Neudesin, Tenascin-X, Actin-related protein 3, Fibulin-1, Moesin, Secretogranin-2, CD63 antigen, tropomyosin 3, 14-3-3 protein beta/alpha and Calnexin. These results have added to our knowledge of symptoms that differentiate NEN patients from functional conditions, individualising rectal NEN patient care, NENs identified through BCSPs, NT-proBNP for screening for CHD and proteins of interest for future study in pNENs. These span the domains of personalised medicine from symptom onset through to diagnostic and biomarker strategies.

Published
2019

121. Iron Fortification Strategies in Brazil

Author

Lamounier, Joel Alves, Capanema, Flávio Diniz, de Oliveira, José Eduardo Dutra, da Silva Rocha, Daniela, de Almeida, Carlos Alberto Nogueira, Preedy, Victor R., editor, Srirajaskanthan, Rajaventhan, editor, and Patel, Vinood B., editor

Published
2013
Full Text
View/download PDF

141. Cheese Fortification

Author

Lacroix, Monique, Han, Jaejoon, Britten, Michel, Champagne, Claude P., Fustier, Patrick, Preedy, Victor R., editor, Srirajaskanthan, Rajaventhan, editor, and Patel, Vinood B., editor

Published
2013
Full Text
View/download PDF

145. Market Potential of Folate Biofortified Rice in China

Author

De Steur, Hans, Gellynck, Xavier, Blancquaert, Dieter, Storozhenko, Sergei, Liqun, Ge, Lambert, Willy, Van Der Straeten, Dominique, Viaene, Jacques, Preedy, Victor R., editor, Srirajaskanthan, Rajaventhan, editor, and Patel, Vinood B., editor

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results